Stoke Therapeutics (STOK) Earnings Date & Reports

Key Takeaways

• Stoke Therapeutics reported a Q3 2026 net loss of $73.6 million, or $1.08 per share, compared with a loss of $38.3 million, or $0.65 per share, a year earlier.
• Quarterly revenue rose to $11.3 million from $10.6 million a year ago, topping the consensus estimate of roughly $8.21 million, while the per-share loss missed the consensus estimate of about -$0.93.
• Rising spending was driven by the advancement of zorevunersen, the company's investigational medicine for Dravet syndrome, including its Phase 3 EMPEROR study.
• The company held $358.8 million in cash, cash equivalents, and marketable securities as of September 30, 2026, which it expects to fund operations into early 2028.
• Management reaffirmed a Phase 3 data readout anticipated in the third quarter of 2027, followed by a planned U.S. NDA (New Drug Application) submission in the second half of 2027.
• For additional context on the company's Major News, Today's Price Move, Price Targets, and Forecast, explore these dedicated pages.
• Explore Trending AI Robots for AI-driven trading ideas and market insights.

Earnings Context and Why It Matters

Stoke Therapeutics is a clinical-stage biotechnology company focused on RNA-based medicines, with its lead candidate zorevunersen targeting Dravet syndrome, a severe genetic epilepsy. Because the company generates most of its revenue from collaboration and licensing agreements rather than product sales, investors focus less on the top line and more on clinical progress, cash runway, and spending discipline. This quarter's results matter because they arrive as the Phase 3 EMPEROR trial moves toward a pivotal readout. Rising research and development (R&D) and launch-readiness costs underscore the company's transition toward a potential first regulatory approval, making the balance sheet and trial milestones the central considerations for shareholders.

Reported Results

For the three months ended September 30, 2026, Stoke Therapeutics recognized revenue of $11.3 million, up from $10.6 million in the same period of 2025. The revenue reflects satisfaction of contractual obligations under collaboration and licensing agreements with Acadia and Biogen.

The company posted a net loss of $73.6 million, or $1.08 per share, compared with a net loss of $38.3 million, or $0.65 per share, a year earlier. The wider loss was driven by higher operating expenses. R&D expenses climbed to $59.8 million from $37.7 million, while selling, general and administrative (SG&A) expenses rose to $28.7 million from $16.0 million, reflecting increased personnel and launch-readiness spending.

Against consensus, the per-share loss of -$1.08 was wider than the roughly -$0.93 analysts expected, while revenue of $11.25 million beat the consensus estimate of approximately $8.21 million. On a year-to-date basis, revenue fell to $26.8 million from $183.0 million, primarily because the prior-year period included recognition of a $150.8 million Biogen intellectual property license obligation. The nine-month net loss was $185.3 million, or $2.81 per share, versus net income of $51.0 million a year earlier.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking clinical-stage biotech names like Stoke Therapeutics, the AI Screener offers a structured way to surface comparable opportunities and monitor emerging signals.

Market Reaction and Investor Sentiment

Investor attention around Stoke Therapeutics remains anchored to the zorevunersen program rather than quarterly revenue, which is collaboration-driven and can fluctuate significantly. The wider-than-expected per-share loss reflects a deliberate increase in investment ahead of the Phase 3 EMPEROR readout, and the company's cash position, expected to fund operations into early 2028, provides runway beyond the anticipated data milestone. Sentiment heading into the quarter was already shaped by the trial's enrollment completion and the company's plan to use a multi-component Vineland-3 assessment for its U.S. regulatory filing. The results themselves are likely to be interpreted primarily through the lens of execution risk and spending trajectory as the pivotal data event approaches.

Forward Outlook and Key Factors to Monitor

The most important catalyst for Stoke Therapeutics remains the Phase 3 EMPEROR study of zorevunersen. Management expects a data readout in the third quarter of 2027, followed by a planned U.S. NDA submission to the U.S. Food and Drug Administration (FDA) in the second half of 2027.

Investors should watch for updates on the trial's primary endpoint, the change in major motor seizure frequency, as well as the key secondary endpoint measuring changes in cognition and behavior. The company's decision to use a multi-component assessment of four Vineland-3 subdomains for the regulatory filing is a notable development that may shape how the data are evaluated.

On the financial side, cost trends will remain in focus. R&D and SG&A expenses have risen materially year over year, and continued spending on launch readiness could keep operating losses elevated. The cash balance of $358.8 million, expected to support operations into early 2028, provides a financial cushion through the readout, but investors will monitor any changes to that runway guidance.

Finally, broader industry dynamics in rare-disease and neurology drug development, including regulatory expectations and competitive positioning in Dravet syndrome treatment, will be worth tracking as the company moves toward a potential first approval.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations